Montez-Rath Maria E, Garcia Pablo, Han Jialin, Cadden LinaCel, Hunsader Patti, Morgan Curt, Kerschmann Russell, Beyer Paul, Dittrich Mary, Block Geoffrey A, Anand Shuchi, Parsonnet Julie, Chertow Glenn M
Department of Medicine (Nephrology), Stanford University.
Ascend Clinical Laboratory.
medRxiv. 2022 Mar 18:2022.03.15.22272426. doi: 10.1101/2022.03.15.22272426.
It is unclear whether a third dose of mRNA platform vaccines, or antibody response to prior infection or vaccination confer protection from the Omicron variant among patients receiving dialysis.
Monthly since February 2021, we tested plasma from 4,697 patients receiving dialysis for antibodies to the receptor-binding domain (RBD) of SARS-CoV-2. We assessed semiquantitative median IgG index values over time among patients vaccinated with at least one dose of the two mRNA vaccines. We ascertained documented COVID-19 diagnoses after December 25, 2021 and up to January 31, 2022. We estimated the relative risk for documented SARS-CoV-2 infection by vaccination status using a log-binomial model accounting for age, sex, and prior clinical COVID-19. Among patients with RBD IgG index value available during December 1-December 24, 2021, we also evaluated the association between the circulating RBD IgG titer and risk for Omicron variant SARS-CoV-2 infection.
Of the 4,697 patients we followed with monthly RBD assays, 3576 are included in the main analysis cohort; among these, 852 (24%) were unvaccinated. Antibody response to third doses was robust (median peak index IgG value at assay limit of 150, equivalent to 3270 binding antibody units/mL). Between December 25-January 31, 2022, SARS-CoV-2 infection was documented 340 patients (7%), 115 (36%) of whom were hospitalized. The final doses of vaccines were given a median of 272 (25 , 75 percentile, 245-303) days and 58 (25 , 75 percentile, 51-95) days prior to infection for the 1-2 dose and 3 dose vaccine groups respectively. Relative risks for infection were higher among patients without vaccination (RR 2.1 [95%CI 1.6, 2.8]), and patients with 1-2 doses (RR 1.3 [95%CI 1.0, 1.8]), compared with patients with three doses of the mRNA vaccines. Relative risks for infection were higher among patients with RBD index values < 23 (506 BAU/mL), compared with RBD index value ≥ 23 (RR 2.4 [95%CI 1.9, 3.0]). The higher risk for infection among patients with RBD index values < 23 was present among patients who received three doses (RR 2.1 [95%CI 1.3, 3.4]).
Among patients receiving hemodialysis, patients unvaccinated, without a third mRNA vaccine dose, or those lacking robust circulating antibody response are at higher risk for Omicron variant infection. Low circulating antibodies could identify the subgroup needing intensified surveillance, prophylaxis or treatment in this patient population.
目前尚不清楚第三剂信使核糖核酸(mRNA)平台疫苗,或既往感染或接种疫苗后的抗体反应,是否能为接受透析的患者提供针对奥密克戎变异株的保护。
自2021年2月起,我们每月检测4697例接受透析患者的血浆中针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)受体结合域(RBD)的抗体。我们评估了至少接种一剂两种mRNA疫苗的患者随时间变化的半定量IgG指数中值。我们确定了2021年12月25日之后至2022年1月31日期间确诊的新冠病毒病病例。我们使用考虑年龄、性别和既往临床新冠病毒病的对数二项式模型,估计了按疫苗接种状况划分的SARS-CoV-2感染记录的相对风险。在2021年12月1日至12月24日期间有RBD IgG指数值的患者中,我们还评估了循环RBD IgG滴度与奥密克戎变异株SARS-CoV-2感染风险之间的关联。
在我们每月进行RBD检测的4697例患者中,3576例纳入主要分析队列;其中,852例(24%)未接种疫苗。对第三剂疫苗的抗体反应强烈(检测限为150时IgG指数峰值中值,相当于3270结合抗体单位/毫升)。在2022年12月25日至1月31日期间,记录到340例患者(7%)感染SARS-CoV-2,其中115例(36%)住院。1-2剂疫苗组和3剂疫苗组在感染前最后一剂疫苗接种的中位时间分别为272天(四分位数间距,245 - 303天)和58天(四分位数间距,51 - 95天)。与接种三剂mRNA疫苗的患者相比,未接种疫苗的患者(相对风险2.1 [95%置信区间1.6, 2.8])和接种1-2剂疫苗的患者(相对风险1.3 [95%置信区间1.0, 1.8])感染风险更高。与RBD指数值≥23的患者相比,RBD指数值<23(506 BAU/毫升)的患者感染风险更高(相对风险2.4 [95%置信区间1.9, 3.0])。RBD指数值<23的患者中感染风险较高的情况在接种三剂疫苗的患者中也存在(相对风险2.1 [95%置信区间1.3, 3.4])。
在接受血液透析的患者中,未接种疫苗、未接种第三剂mRNA疫苗或缺乏强烈循环抗体反应的患者感染奥密克戎变异株的风险更高。低循环抗体水平可识别出该患者群体中需要加强监测、预防或治疗的亚组。